Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral fludarabine + oral cyclophosphamide + subcutaneous alemtuzumab for refractory or relapsed B-cell chronic lymphocytic leukemia
2005-000121-30Phase 2Completed
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Nov 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and Neoplasm, sponsored by ASST Grande Ospedale Metropolitano Niguarda. Primary endpoint: Overall response rate (complete remission + partial response). Started Nov 2007; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Neoplasm
Beyond the preview
Go deeper on 2005-000121-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000121-30.